This systematic review aims to critically evaluate RCTs investigating ACE inhibitors and ARBs in CKD, with a focus on their effects on albuminuria/proteinuria, rate of eGFR decline, and safety outcomes. This evidence concerns the gene ACE and chronic kidney disease.